Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests?

Hepatology

Volumn 37, Issue 5, 2003, Pages 972-974

  Afdhal, Nezam H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA INTERFERON; ANTIFIBROTIC AGENT; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; HAPTOGLOBIN; HYALURONIC ACID; RIBAVIRIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ALCOHOL CONSUMPTION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; PATHOLOGY; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE COUNT;

EID: 0037698889     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50223     Document Type: Editorial

References (21)

1. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1430.
2. Dienstag JL. The role of liver biopsy in chronic hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S152-S160.
3. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996;24:289-293.
4. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
5. Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos M, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gatrointest Endosc 1996;43:568-571.
6. Colombo M, Del Ninno E, de Franchis R, De Fazio C, Festorazzi S, Ronchi G, Tommasini MA. Ultrasound assisted percutaneous liver biopsy: superiority of the Trucut over the Menghini needle for the diagnosis of cirrhosis. Gastroenterology 1988;95:487-489.
7. Vargas-Tank L, Martinez V, Jiron MI, Soto JR, Armas Merino R. tru-cut and Menghini needles: different yields in the histological diagnosis of liver disease. Liver 1985;5:178-181.
8. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales F, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
11. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez Bauer E, Bruguera M, et al. Identification of chronic hepatitis C without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002;36:986-992.
12. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
13. Patel K, Gordon SC, Oh E, Smith K, McHutchison JG. A non invasive panel of serum fibrosis markers can reliably differentiate hepatitis C patients with minimal fibrosis from those with fibrosis stage F2-F4 [Abstract]. HEPATOLOGY 2002;36(Part 2):355A.
14. Oh S, Afdhal NH. Hepatic fibrosis; are any of the serum markers really useful? Curr Gastroenterol Rep 2001;3:12-18.
15. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38(Suppl):S38-S53.
16. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S57-S64.
17. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, Maiga MY, et al. Histopathological evaluation of liver fibrosis:quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28:439-446.
18. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, et al. Prediction of progressive liver fibrosis in hepatitis C by serum and tissue levels of transforming growth factor beta. J Viral Hep 2001;8:430-437.
19. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-1616.
20. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawa M, et al. Circulating matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase -1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583.
21. Rosenberg W, Burt A, Hubscher S, Roskams T, Voelker M, Becka M, Arthur MJ. Serum markers predict liver fibrosis [Abstract]. HEPATOLOGY 2002;36(Part 2):355A.